<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04150289</url>
  </required_header>
  <id_info>
    <org_study_id>20192475</org_study_id>
    <nct_id>NCT04150289</nct_id>
  </id_info>
  <brief_title>A Disease Registry Encompassing the Care Of Patients With Multiple Myeloma on Panobinostat</brief_title>
  <acronym>RECOMM</acronym>
  <official_title>A Disease Registry Encompassing the Care of Patients With Multiple Myeloma on Panobinostat (RECOMM)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>SecuraBio</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>SecuraBio</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to describe current treatment patterns in the real-world setting among
      patients with multiple myeloma who are initiating treatment with (or changing treatment to)
      panobinostat and explore the associations with baseline patient characteristics, healthcare
      resource utilization, and clinical outcomes.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">November 2019</start_date>
  <completion_date type="Anticipated">November 2021</completion_date>
  <primary_completion_date type="Anticipated">November 2021</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Ecologic or Community</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>24 Months</target_duration>
  <primary_outcome>
    <measure>Response to treatment</measure>
    <time_frame>24 months</time_frame>
    <description>Looking for patient reproted response to treatment with panobinostat</description>
  </primary_outcome>
  <enrollment type="Anticipated">160</enrollment>
  <condition>Multiple Myeloma</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Farydak</intervention_name>
    <description>non-interventional study</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        The study population will be any adult who is clinically diagnosed with multiple myeloma
        who is actively taking panobinostat.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Willing and able to provide written informed consent

          -  At least 18 years of age

          -  Clinical diagnosis of multiple myeloma that meets published diagnostic criteria

          -  Initiating panobinostat within 60 days of enrollment

          -  ECOG performance status 0-1

          -  Availability of documentation from the patient's medical records regarding previous
             myeloma treatment, response, and duration of response

          -  Willing and able to complete the PRO questionnaire

        Exclusion Criteria:

          -  Diagnosed with any B-cell malignancy other than myeloma

          -  Estimated life expectancy &lt;6 months

          -  Currently enrolled in any interventional clinical trial at study entry (note: patients
             who enroll in an interventional clinical trial after enrollment may remain in the
             registry)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Lauren Travis</last_name>
    <phone>803-329-7772</phone>
    <email>ltravis@ccorn.net</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Debra Litwak</last_name>
    <phone>8054797793</phone>
    <email>dlitwak@securabio.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Carolina Blood and Cancer Care Associates</name>
      <address>
        <city>Rock Hill</city>
        <state>South Carolina</state>
        <zip>29732</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Taylor Barnes</last_name>
      <phone>803-329-7772</phone>
      <email>tbarnes@cbcca.net</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>October 31, 2019</study_first_submitted>
  <study_first_submitted_qc>October 31, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 4, 2019</study_first_posted>
  <last_update_submitted>October 31, 2019</last_update_submitted>
  <last_update_submitted_qc>October 31, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 4, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Farydak</keyword>
  <keyword>panobinostat</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Panobinostat</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

